SS
PNT

Steve Schonfeld’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Steve Schonfeld’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,192
Closed -$88.9K – 2836
2022
Q4 		$88.9K Sell
12,192
-208
-2% -$1.54K ﹤0.01% 2207
2022
Q3 		$96K Buy
+12,400
New +$105K ﹤0.01% 2569

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Steve Schonfeld's PNT Position: Q1 2023 in Review

Steve Schonfeld sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q1 2023, closing a stake of 12,192 shares — an estimated $88.9K sold.

Steve Schonfeld first reported a position in PNT in Q3 2022 and held it in 2 quarters. The position peaked at $96K in Q3 2022. 115 funds tracked by Wall St. Rank hold PNT as of Q1 2023.

  • Steve Schonfeld reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Steve Schonfeld sold 12,192 POINT Biopharma Global Inc. Common Stock shares in Q1 2023, an estimated $88.9K.
  • Steve Schonfeld first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Steve Schonfeld's POINT Biopharma Global Inc. Common Stock position peaked at $96K in Q3 2022.
  • 115 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.